Danaher (NYSE:DHR) Price Target Raised to $255.00

Danaher (NYSE:DHR) had its price objective increased by Barclays from $230.00 to $255.00 in a report published on Wednesday,Benzinga reports. They currently have an overweight rating on the conglomerate’s stock.

A number of other equities analysts have also commented on the stock. Weiss Ratings upgraded shares of Danaher from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, September 16th. Stifel Nicolaus dropped their price objective on shares of Danaher from $260.00 to $220.00 and set a “buy” rating for the company in a report on Wednesday, July 22nd. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $240.00 target price on shares of Danaher in a research note on Wednesday, July 22nd. Piper Sandler assumed coverage on Danaher in a report on Thursday, June 11th. They issued a “neutral” rating and a $200.00 target price on the stock. Finally, TD Cowen decreased their price target on Danaher from $240.00 to $236.00 and set a “buy” rating on the stock in a research report on Wednesday, July 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, Danaher presently has an average rating of “Moderate Buy” and a consensus target price of $235.23.

Danaher Stock Performance

Danaher stock opened at $220.15 on Wednesday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. The stock has a fifty day moving average price of $211.38 and a two-hundred day moving average price of $194.62. Danaher has a 52-week low of $160.93 and a 52-week high of $242.80. The firm has a market capitalization of $154.76 billion, a P/E ratio of 39.10, a P/E/G ratio of 2.71 and a beta of 0.76.

Danaher (NYSE:DHR) last issued its earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, beating the consensus estimate of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The company had revenue of $6.26 billion for the quarter, compared to the consensus estimate of $6.12 billion. During the same quarter in the previous year, the company earned $0.77 EPS. The firm’s revenue for the quarter was up 5.5% compared to the same quarter last year. As a group, analysts anticipate that Danaher will post 8.53 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a dividend of $0.40 per share. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. Danaher’s dividend payout ratio is presently 28.42%.

Institutional Investors Weigh In On Danaher

Several institutional investors have recently modified their holdings of DHR. BlackRock Inc. acquired a new position in shares of Danaher in the 2nd quarter valued at approximately $10,492,520,000. Jupiter Topco LLC acquired a new position in shares of Danaher in the second quarter valued at approximately $1,456,317,000. Generation Investment Management LLP bought a new stake in shares of Danaher during the second quarter worth $1,287,949,000. Bank of America Corp DE acquired a new stake in shares of Danaher during the second quarter worth $993,846,000. Finally, Legal & General Group Plc bought a new stake in Danaher in the 2nd quarter valued at $801,056,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.